Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis

Journal of Clinical Investigation

Volumn 108, Issue 12, 2001, Pages 1825-1832

  Plater Zyberk, Christine ^a   Joosten, Leo A B ^b   Helsen, Monique M A ^b   Sattonnet Roche, Pascale ^a   Siegfried, Christiane ^a   Alouani, Sami ^a   Van De Loo, Fons A J ^b   Graber, Pierre ^a   Aloni, Shuki ^c   Cirillo, Rocco ^d   Lubberts, Erik ^b   Dinarello, Charles A ^e   Van Den Berg, Wim B ^b   Chvatchko, Yolande ^a  

^a SERONO PHARMACEUTICAL RES INSTITUTE   (Switzerland)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c InterPharm Laboratories   (Israel)

^d Istituto di Ricerche Biomediche Antoine Marxer SpA   (Italy)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 18; INTERLEUKIN 6; MATRIX PROTEIN; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT INTERLEUKIN 18; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CARTILAGE DEGENERATION; CARTILAGE MATRIX; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SYNOVITIS;

ANIMALS; ARTHRITIS; COLLAGEN; GLYCOPROTEINS; IMMUNOGLOBULIN G; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON TYPE II; INTERLEUKIN-18; INTERLEUKIN-6; MALE; MICE; MICE, INBRED DBA; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035664487     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200112097     Document Type: Article

References (36)

1. Endotoxin-induced serum factor that stimulates gamma interferon production
2. Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein
3. IFN-gamma-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12
4. Interleukin-18: A novel cytokine that augments both innate and acquired immunity
5. Interleukin-18 (IFN-γ-inducing factor) induces IL-8 and IL-1β via TNF-α production from non-CD14+ human blood mononuclear cells
6. Interleukin 18, a cytokine which resembles IL-1 structurally and IL-12 functionally but exerts its effect independently of both
7. Cloning of a new cytokine that induces IFNgamma production by T cells
8. Defective NK cell activity and Th1 response in IL18-deficient mice
9. Activation of interferon-gamma inducing factor mediated by interleukin-1beta converting enzyme
10. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development
11. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor
12. IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses
13. Interleukin-18 (interferon-gamma-inducing factor) is produced by osteoblasts and acts via granulocyte/macrophage colony-stimulating factor and not via interferon-gamma to inhibit osteoclast formation
14. The role of IL-18 in innate immunity
15. Interleukin-18, a proinflammatory cytokine
16. A proinflammatory role for IL-18 in rheumatoid arthritis
17. Interleukin-1beta-converting enzyme/caspase-1 in human osteoarthritic tissues: Localization and role in the maturation of interleukin-1 beta and interleukin 18
18. An IFN-gamma-independent proinflammatory role of IL-18 in murine streptococcal cell wall arthritis
19. Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response
20. Cloning and expression of interleukin-18 binding protein
21. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18
22. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40
23. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
24. Marked amelioration of established collagen-induced arthritis by treatment with antibodies to CD23 in vivo
25. Anti-CD5 therapy decreases severity of established disease in collagen type II-induced arthritis in DBA/1 mice
26. Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction
27. Interleukin-18 regulation of interferon gamma production and cell proliferation as shown in interleukin-1beta-converting enzyme (caspase-1)-deficient mice
28. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation
29. Cartilage oligomeric matrix protein (COMP)-induced arthritis in rats
30. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis
31. IL-1H, an interleukin 1-related protein that binds IL18 receptor/IL-1Rrp
32. Identification and initial characterization of four novel members of the interleukin-1 family
33. Distinct roles for the NF-κB1 (p50) and c-Rel transcription Factors in inflammatory arthritis
34. Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18
35. Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis
36. Interleukin-18 can promote synovial inflammation through activation of peripheral blood and synovial neutrophils